myocardial infarction

Capricor Therapeutics (CAPR) has signed a collaboration agreement and exclusive licensing option with Janssen Biotech (Janssen), a Johnson & Johnson company, for the development of new cardiovascular products.

Under the deal, both the firms agreed to collaborate on the development of Capricor’s cell therapy programme for cardiovascular applications, including its lead product, CAP-1002, an allogeneic cardiosphere-derived cell (CDC) therapeutic under evaluation in patients who have suffered a large myocardial infarction.

Following the deal, both companies will collaborate on elements of cell manufacturing development.

The deal will see Capricor contribute to the costs of the manufacturing collaboration and receive an upfront payment of $12.5m from Janssen.

As part of the deal, Janssen has the right to enter into an exclusive licence agreement for CAP-1002 at any time until 60 days after delivery by Capricor of the six-month follow-up results from Phase II of Capricor’s ALLSTAR clinical trial for CAP-1002.

"The deal will see Capricor contribute to the costs of the manufacturing collaboration and receive an upfront payment of $12.5m from Janssen."

Capricor will also be eligible to receive about $325m in additional payments, if Janssen exercises its option rights, as well as royalties that would be paid on commercial sales of CAP-1002.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Capricor CEO Linda Marban said the collaboration with Janssen is an important validation of the company’s lead product CAP-1002.

"We are proud to be working with Janssen to support the continued development of CAP-1002 and for the additional non-dilutive capital to further our research and development that will add to our pipeline," Marban said.

Capricor is mainly focused on the development of novel therapeutics to prevent and treat heart disease, has two leading product candidates including CAP-1002 and Cenderitide.

Image: Myocardial infarction of the tip of the anterior wall of the heart (2). Photo: courtesy of JHeuser.